Thus, given the recent approval of the drug, one can consider RPE65-mediated IRDs as an example of retinal dystrophy with a definite genetic diagnosis but a highly variable phenotypic presentation in patients carrying this genetic mutation that can manifest itself in different types of IRDs. Here, RPE65 is linked to Retinal dystrophy.